CY1111467T1 - Μορια ανθρωπινου αντισωματος για την il-13 - Google Patents

Μορια ανθρωπινου αντισωματος για την il-13

Info

Publication number
CY1111467T1
CY1111467T1 CY20111100456T CY111100456T CY1111467T1 CY 1111467 T1 CY1111467 T1 CY 1111467T1 CY 20111100456 T CY20111100456 T CY 20111100456T CY 111100456 T CY111100456 T CY 111100456T CY 1111467 T1 CY1111467 T1 CY 1111467T1
Authority
CY
Cyprus
Prior art keywords
motorcycle
ill
human response
antibody molecules
hodgkin
Prior art date
Application number
CY20111100456T
Other languages
Greek (el)
English (en)
Inventor
Phillip David Monk
Lutz Jermutus
Ralph Raymond Minter
Celia Patricia Shorrock
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of CY1111467T1 publication Critical patent/CY1111467T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20111100456T 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13 CY1111467T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
EP04743400A EP1646656B1 (en) 2003-07-15 2004-07-15 Human antibody molecules for il-13

Publications (1)

Publication Number Publication Date
CY1111467T1 true CY1111467T1 (el) 2015-08-05

Family

ID=44535047

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100456T CY1111467T1 (el) 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13

Country Status (8)

Country Link
JP (3) JP5519567B2 (https=)
KR (1) KR101073590B1 (https=)
AU (1) AU2011200308B2 (https=)
CY (1) CY1111467T1 (https=)
HK (1) HK1216427A1 (https=)
MX (1) MXPA06000258A (https=)
NO (2) NO338853B1 (https=)
RU (1) RU2009148270A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027797A2 (pt) * 2014-06-18 2017-10-31 Medimmune Llc métodos e meios de cultura de células compreendendo n-acetilcisteína

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656947A1 (en) * 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US20040023337A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
AU2002359568B2 (en) * 2001-12-03 2008-02-21 Alexion Pharmaceuticals, Inc. Hybrid antibodies
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
JP2014101372A (ja) 2014-06-05
NO20160707A1 (no) 2016-04-27
HK1155185A1 (en) 2012-05-11
JP5922686B2 (ja) 2016-05-24
AU2011200308B2 (en) 2011-07-28
JP2011147454A (ja) 2011-08-04
HK1097853A1 (en) 2007-07-06
JP2016047843A (ja) 2016-04-07
KR20060054312A (ko) 2006-05-22
MXPA06000258A (es) 2006-07-03
KR101073590B1 (ko) 2011-10-14
NO338853B1 (no) 2016-10-24
NO342727B1 (no) 2018-07-30
NO20060730L (no) 2006-04-10
HK1216427A1 (zh) 2016-11-11
AU2011200308A1 (en) 2011-02-17
JP5519567B2 (ja) 2014-06-11
RU2009148270A (ru) 2011-06-27

Similar Documents

Publication Publication Date Title
MY144906A (en) Human antibodies against il13 and therapeutic uses
WO2005007699A3 (en) Human antibody molecules for il-13
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
TNSN08333A1 (en) Thymic stromal lymphopoietin (tslp) antibodies and uses thereof
CY1120887T1 (el) Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους
CY2021009I2 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
NO20054223L (no) Antistoffmolekyler som har spesifisitet for human IL-1beta
MX2009010765A (es) Anticuerpos anti-ige.
EP1850799A4 (en) METHOD AND DEVICE FOR TREATING SPINALSTENOSIS
EP1363632A4 (en) SELECTIVE CANNABIMIMETIC AMINOALKYLINDOLES OF A RECEPTOR
CY2014007I1 (el) Μεθοδοι για την αγωγη διαταραχων ή παθησεων που συσχετιζονται με υπερλιπιδαιμια και υπερχοληστερολαιμια ενω ελαχιστοποιουνται οι παρενεργειες
DK1765322T3 (da) Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
DK1593387T3 (da) Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser
CY1111467T1 (el) Μορια ανθρωπινου αντισωματος για την il-13
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
EP1765331A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF LUNG DISEASES
WO2006048781A3 (en) IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
Khaniyan et al. Understanding exercise behavior among Tehran adolescent girls according
Habibi et al. Effectiveness of dialectical behavior therapy in improving symptoms of patients with dysthymic disorder
Kang et al. A Study on Psychological Effect of Natural Element in Rest Space of Office
TH98075B (th) แอนตี้-tslp แอนตี้บอดี้
Barthelat 5 The Modeling of Time Dependent Mechanical Properties of Cervine Enamel
UA97232C2 (ru) Изолированное антитело, которое связывает моноцитный хемоатрактантный белок 1 (мср-1) человека
IL186666A0 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases